WASHINGTON — Drug makers and their lobbyists are struggling to agree on a strategy that would convince President Trump to back off a highly controversial drug pricing policy that he vowed to enact on Monday.

This week, the group, the Pharmaceutical Research and Manufacturers of America convened three calls with member companies to discuss how to respond to an ultimatum that Trump laid out in July. He said then that the industry would have to come up with a way to significantly lower drug prices before August 24, or his administration would enact a policy, despised by the industry, that would tie what the U.S. pays for drugs to what other countries pay.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • let AMERICA pay for what other country’s get at a DEEP % DISCOUNT… how about dollar cost averaging the top 10 country’s they sell the product to and use that as the COST BASIS…. this way every one carries the freight ?

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy